Aethlon Medical, Inc. (AEMD)

Aethlon Medical, Inc.'s stock price has experienced significant volatility. The share price declined by 63.18% between January 7, 2025, and January 6, 2026, and decreased by approximately 95.54% to 95.99% over the past year. In August 2025, the stock surged by 62.61% following positive market sentiment driven by news of the completion of the first cohort in the Australian Hemopurifier cancer trial with positive outcomes. During this period, the company also reported significant operational cost reductions of 31.6%. Other notable events include Aethlon Medical announcing a $3.3 million private placement and a $4.5 million public offering of common stock and warrants. The company also secured patents for Hemopurifier use in Long COVID and CAC treatments and reported cutting losses in fiscal Q1.

Specific information regarding demand seasonality for Aethlon Medical, Inc.'s products and services is not explicitly detailed in the provided search results. Demand is likely driven by medical necessity and clinical advancements rather than typical seasonal consumer patterns.

Aethlon Medical, Inc. (AEMD) is a medical technology company focused on developing products for diagnosing and treating life and organ-threatening diseases. The company operates within the Healthcare sector, specifically in the Medical/Dental Instruments, Biotechnology, and Medical Specialties industries. Its primary product is the Aethlon Hemopurifier®, a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The Hemopurifier® has received "Breakthrough Device" designation from the FDA for treating individuals with advanced or metastatic cancer and for life-threatening viruses. Aethlon Medical operates through two segments: Aethlon, which handles therapeutic business activities, and ESI, which focuses on diagnostic business activities.

Aethlon Medical, Inc. is headquartered in San Diego, California, and is actively expanding its clinical development efforts internationally. The company is conducting safety, feasibility, and dose-finding clinical trials for the Hemopurifier® in cancer patients with solid tumors in Australia and India.

Aethlon Medical's brand reputation appears to be influenced by its clinical trial progress and financial performance. Analyst ratings for AEMD currently have a consensus of "Reduce" or "Hold". Positive market sentiment and a stock surge in August 2025 followed the announcement of positive outcomes from the Australian Hemopurifier cancer trial and significant cost reductions. The FDA's "Breakthrough Device" designation for the Hemopurifier® also enhances the company's standing in the medical community. However, the company faces challenges, including reported net losses and risks associated with clinical trial failures and an untested commercialization strategy, which can impact its overall reputation.

The ownership structure of Aethlon Medical, Inc. is a mix of institutional, insider, and retail investors. Insiders hold a significant portion, with some reports indicating 4,258.53% or 54.40% of the company's stock, while retail investors hold approximately 43.87% of the stock. Institutional ownership is relatively low, reported at around 1.73% to 6.03%. Major individual shareholders include Family Revocable Trust Ellen R. Weiner and Phillip A. Ward. Top institutional holders include Armistice Capital, LLC, Ikarian Capital, LLC, and Boothbay Fund Management, LLC.